# Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer

> **NCT00983580** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 107 (actual)

## Conditions studied

- Adenomatous Polyp

## Interventions

- **DRUG:** Aspirin
- **DRUG:** Eflornithine
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Placebo
- **OTHER:** Telephone-Based Intervention

## Key facts

- **NCT ID:** NCT00983580
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08-20
- **Primary completion:** 2016-10-07
- **Final completion:** 2019-08-13
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2019-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00983580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00983580, "Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00983580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*